Neuromyelitis Optica

This case-control study investigates whether a rapid enzyme immunodot assay is equivalent to the gold standard cell-based assay for detecting immunoglobulin G autoantibodies against aquaporin 4 (AQP4) in patients with neuromyelitis optica spectrum disorder (NMOSD).

This cross-sectional study examines laboratory and imaging data for patients with demyelinating central nervous system disease to investigate the frequency of MOG-IgA and associated clinical features.

This case report describes a man aged 58 years who presented with intermittent chest pain, numbness and tingling of the upper extremities, and a violaceous, reticular rash on his lower extremities, abdomen, and flank.

This narrative review provides a contemporary synthesis of evidence examining health disparities, inequities, and social determinants of health in US Black and Hispanic or Latinx patients with multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody disorders.

A 67-year-old woman with fibromyalgia presents with sequential bilateral vision loss; scalp tenderness; jaw claudication; neck, shoulder, and back pain; and recent weight loss. What is your diagnosis?

This study details a case of biotinidase deficiency mimicking neuromyelitis optica spectrum disorders and reviews prior cases of biotinidase deficiency that met Wingerchuck 2015 criteria for neuromyelitis optica spectrum disorder.

This study evaluates the proportion of patients with myelin oligodendrocyte glycoprotein IgG–associated disorders who fulfill the seronegative neuromyelitis optica spectrum disorder criteria.

This cohort study reports outcomes of long-term follow-up in patients with myelin oligodendrocyte glycoprotein antibody–associated disorder.

This Viewpoint summarizes the current knowledge of the clinical, radiologic, and immunologic features of adult patients who are positive for anti–myelin oligodendrocyte glycoprotein and compares these individuals with patients with multiple sclerosis and patients with neuromyelitis optica.

This multinational cohort study examines the clinical phenotypes, treatment responses, and outcomes of children with relapsing myelin oligodendrocyte glycoprotein antibody–associated disease.

This cross-sectional study examines adaptive visual network connectivity changes in neuromyelitis optica spectrum disorder.

This study examines the safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder.

This study evaluates whether longitudinally extensive cervical cord lesions extending to or accompanied by area postrema/dorsal medulla lesions on magnetic resonance imaging are specific for neuromyelitis optica spectrum disorders.

This systematic review and meta-analysis evaluates the efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders, considering the potential predictive factors related to patient response to rituximab in this disease.